Pironetin reacts covalently with cysteine-316 of α-tubulin to destabilize microtubule

Nature Communications

Volumn 7, Issue , 2016, Pages

  Yang, Jianhong ^a   Wang, Yuxi ^a   Wang, Taijing ^a   Jiang, Jian ^b   Botting, Catherine H ^c   Liu, Huanting ^c   Chen, Qiang ^a   Yang, Jinliang ^a   Naismith, James H ^a,c   Zhu, Xiaofeng ^a,b   Chen, Lijuan ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TUBULIN; ANTINEOPLASTIC AGENT; BETA TUBULIN; BETA2 TUBULIN; COLCHICINE; CYSTEINE; LACTONE DERIVATIVE; NATURAL PRODUCT; PIRONETIN; TUBULIN; UNCLASSIFIED DRUG; VINBLASTINE; PYRONE DERIVATIVE;

AMINO ACID; CANCER; CHEMICAL BINDING; DESIGN; DISEASE TREATMENT; DRUG DEVELOPMENT; INHIBITOR; MOLECULAR ANALYSIS; PHYSIOLOGICAL RESPONSE;

ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; COVALENT BOND; CRYSTAL STRUCTURE; CRYSTALLIZATION; CRYSTALLOGRAPHY; DRUG PROTEIN BINDING; HYDROGEN BOND; MICHAEL ADDITION; MICROTUBULE ASSEMBLY; MOLECULAR WEIGHT; PROTEIN CONFORMATION; PROTEIN TARGETING; CHEMISTRY; DRUG EFFECT; ESCHERICHIA COLI; MASS SPECTROMETRY; METABOLISM; MICROTUBULE; MOLECULARLY TARGETED THERAPY;

ESCHERICHIA COLI; MASS SPECTROMETRY; MICROTUBULES; MOLECULAR TARGETED THERAPY; PROTEIN CONFORMATION; PYRONES; TUBULIN;

EID: 84977097910     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms12103     Document Type: Article

References (42)

1. Alberts, B. et al. Molecular Biology of the Cell (Garland Science, 2008)
2. Dumontet, C. & Jordan, M. A. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat. Rev. Drug Discov. 9, 790-803 (2010)
3. Kupchan, S. M. et al. Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus. J. Am. Chem. Soc. 94, 1354-1356 (1972)
4. Kavallaris, M. Microtubules and resistance to tubulin-binding agents. Nat. Rev. Cancer 10, 194-204 (2010)
5. Nogales, E., Wolf, S. G., Khan, I. A., Luduena, R. F. & Downing, K. H. Structure of tubulin at 6.5 and location of the taxol-binding site. Nature 375, 424-427 (1995)
6. Lowe, J., Li, H., Downing, K. H. & Nogales, E. Refined structure of alpha betatubulin at 3.5A resolution. J. Mol. Biol. 313, 1045-1057 (2001)
7. Ravelli, R. B. et al. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 428, 198-202 (2004)
8. Gigant, B. et al. Structural basis for the regulation of tubulin by vinblastine. Nature 435, 519-522 (2005)
9. Prota, A. E. et al. Molecular mechanism of action of microtubule-stabilizing anticancer agents. Science 339, 587-590 (2013)
10. Prota, A. E. et al. A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs. Proc. Natl Acad. Sci. USA 111, 13817-13821 (2014)
11. Prota, A. E. et al. Structural basis of microtubule stabilization by laulimalide and peloruside A. Angew. Chem. Int. Ed. 53, 1621-1625 (2014)
12. Stanton, R. A., Gernert, K. M., Nettles, J. H. & Aneja, R. Drugs that target dynamic microtubules: a new molecular perspective. Med. Res. Rev. 31, 443-481 (2011)
13. Keglevich, P., Hazai, L., Kalaus, G. & Szantay, C. Modifications on the basic skeletons of vinblastine and vincristine. Molecules 17, 5893-5914 (2012)
14. Barker, T. J., Duncan, K. K., Otrubova, K. & Boger, D. L. Potent vinblastine C20 ureas displaying additionally improved activity against a vinblastineresistant cancer cell line. ACS Med. Chem. Lett. 4, 985-988 (2013)
15. Seve, P. & Dumontet, C. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol. 9, 168-175 (2008)
16. Kobayashi, S. et al. Pironetin, a novel plant growth regulator produced by Streptomyces sp. NK10958. II. Structural elucidation. J. Antibiot. (Tokyo) 47, 703-707 (1994)
17. Yasui, K. et al. Chemical modification of PA-48153C, a novel immunosuppressant isolated from Streptomyces prunicolor PA-48153. J. Antibiot. (Tokyo) 49, 173-180 (1996)
18. Torijano-Gutierrez, S. et al. The mechanism of the interactions of pironetin analog/combretastatin A-4 hybrids with tubulin. Arch. Pharm. (Weinheim) 348, 541-547 (2015)
19. Kondoh, M. et al. Cell cycle arrest and antitumor activity of pironetin and its derivatives. Cancer Lett. 126, 29-32 (1998)
20. Yoshida, M. et al. Antiproliferating activity of the mitotic inhibitor pironetin against vindesine- and paclitaxel-resistant human small cell lung cancer H69 cells. Anticancer Res. 27, 729-736 (2007)
21. Kondoh, M., Usui, T., Nishikiori, T., Mayumi, T. & Osada, H. Apoptosis induction via microtubule disassembly by an antitumour compound, pironetin. Biochem. J. 340 Pt 2 411-416 (1999)
22. Usui, T. et al. The anticancer natural product pironetin selectively targets Lys352 of alpha-tubulin. Chem. Biol. 11, 799-806 (2004)
23. Banuelos-Hernandez, A. E., Mendoza-Espinoza, J. A., Pereda-Miranda, R. & Cerda-Garcia-Rojas, C. M. Studies of (-)-pironetin binding to alpha-tubulin: conformation, docking, and molecular dynamics. J. Org. Chem. 79, 3752-3764 (2014)
24. Panos, J. et al. Synthesis and biological evaluation of truncated alpha-tubulinbinding pironetin analogues lacking alkyl pendants in the side chain or the dihydropyrone ring. Org. Biomol. Chem. 11, 5809-5826 (2013)
25. Marco, J. A. et al. Design and synthesis of pironetin analogues with simplified structure and study of their interactions with microtubules. Eur. J. Med. Chem. 46, 1630-1637 (2011)
26. Watanabe, H. et al. Synthesis of pironetin and related analogs: studies on structure-activity relationships as tubulin assembly inhibitors. J. Antibiot. (Tokyo) 53, 540-545 (2000)
27. Nawrotek, A., Knossow, M. & Gigant, B. The determinants that govern microtubule assembly from the atomic structure of GTP-tubulin. J. Mol. Biol. 412, 35-42 (2011)
28. Schuttelkopf, A. W. & van Aalten, D. M. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr. D Biol. Crystallogr. 60, 1355-1363 (2004)
29. Wang, C., Cormier, A., Gigant, B. & Knossow, M. Insight into the GTPase activity of tubulin from complexes with stathmin-like domains. Biochemistry 46, 10595-10602 (2007)
30. Nogales, E., Downing, K. H., Amos, L. A. & Lowe, J. Tubulin and FtsZ form a distinct family of GTPases. Nat. Struct. Biol. 5, 451-458 (1998)
31. Prota, A. E. et al. The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization. J. Mol. Biol. 426, 1848-1860 (2014)
32. Collaborative Computational Project, N. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50, 760-763 (1994)
33. Evans, P. Scaling and assessment of data quality. Acta Crystallogr. D Biol. Crystallogr. 62, 72-82 (2006)
34. Kabsch, W. XDS. Acta Crystallogr. D Biol. Crystallogr. 66, 125-132 (2010)
35. Winter, G. xia2: an expert system for macromolecular crystallography data reduction. J. Appl. Cryst. 43, 5 (2010)
36. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007)
37. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486-501 (2010)
38. Murshudov, G. N. et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. D Biol. Crystallogr. 67, 355-367 (2011)
39. Shevchenko, A., Wilm, M., Vorm, O. & Mann, M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 68, 850-858 (1996)
40. Lin, C. M. & Hamel, E. Effects of inhibitors of tubulin polymerization on GTP hydrolysis. J. Biol. Chem. 256, 9242-9245 (1981)
41. David-Pfeuty, T., Simon, C. & Pantaloni, D. Effect of antimitotic drugs on tubulin GTPase activity and self-assembly. J. Biol. Chem. 254, 11696-11702 (1979)
42. Karplus, P. A. & Diederichs, K. Linking crystallographic model and data quality. Science 336, 1030-1033 (2012)